About Proteon Therapeutics
Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company's product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: PRTO
- Previous Close: $1.90
- 50 Day Moving Average: $1.97
- 200 Day Moving Average: $6.72
- 52-Week Range: $1.75 - $11.63
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.10
- P/E Growth: 0.00
- Market Cap: $31.53M
- Outstanding Shares: 16,594,000
- Beta: 1.72
- Return on Equity: -51.48%
- Return on Assets: -47.65%
Companies Related to Proteon Therapeutics:
- Current Ratio: 9.86%
- Quick Ratio: 9.86%
What is Proteon Therapeutics' stock symbol?
Proteon Therapeutics trades on the NASDAQ under the ticker symbol "PRTO."
Where is Proteon Therapeutics' stock going? Where will Proteon Therapeutics' stock price be in 2017?
8 analysts have issued 1-year price objectives for Proteon Therapeutics' shares. Their forecasts range from $3.00 to $27.00. On average, they anticipate Proteon Therapeutics' stock price to reach $15.71 in the next year.
When will Proteon Therapeutics announce their earnings?
Proteon Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
Who owns Proteon Therapeutics stock?
Proteon Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Deerfield Management Co. (8.03%), Pharmstandard International S.A. (7.02%) and Perceptive Advisors LLC (2.01%). Company insiders that own Proteon Therapeutics stock include Daniel Philip Gottlieb, George Arthur Eldridge and Timothy P Noyes.
Who sold Proteon Therapeutics stock? Who is selling Proteon Therapeutics stock?
Proteon Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Co..
Who bought Proteon Therapeutics stock? Who is buying Proteon Therapeutics stock?
Proteon Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Pharmstandard International S.A. and Perceptive Advisors LLC.
How do I buy Proteon Therapeutics stock?
Shares of Proteon Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Proteon Therapeutics stock cost?
One share of Proteon Therapeutics stock can currently be purchased for approximately $1.90.